ArriVent BioPharma (AVBP) Other Non-Current Assets (2023 - 2026)

ArriVent BioPharma has disclosed Other Non-Current Assets across 4 years of filings, most recently posting $69000.0 for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $69000.0, down 60.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $69000.0 (down 60.8% YoY), and the FY2025 annual result was $190000.0, up 50.79% from the prior year.
• Other Non-Current Assets came in at $69000.0 for Q1 2026 at ArriVent BioPharma, down from $190000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $2.7 million in Q4 2023 to a low of $69000.0 in Q1 2026.
• The 4-year median for Other Non-Current Assets is $151000.0 (2024), against an average of $431100.0.
• Across the five-year window, Other Non-Current Assets plunged 95.39% in 2024 and soared 283.2% in 2025, its largest moves.
• ArriVent BioPharma's Other Non-Current Assets stood at $2.7 million in 2023, then slumped by 95.39% to $126000.0 in 2024, then jumped by 50.79% to $190000.0 in 2025, then slumped by 63.68% to $69000.0 in 2026.
• The last three Other Non-Current Assets figures came in at $69000.0 (Q1 2026), $190000.0 (Q4 2025), and $180000.0 (Q3 2025), per Business Quant data.